{"id":50264,"date":"2025-12-09T13:28:20","date_gmt":"2025-12-09T05:28:20","guid":{"rendered":"https:\/\/flcube.com\/?p=50264"},"modified":"2025-12-09T13:28:21","modified_gmt":"2025-12-09T05:28:21","slug":"ignis-therapeutics-cenobamate-nmpa-approval-targets-epilepsy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50264","title":{"rendered":"Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy"},"content":{"rendered":"\n<p><strong>Ignis Therapeutics<\/strong> announced that <strong>cenobamate tablets<\/strong> received marketing approval from China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>partial seizures in adult patients with epilepsy<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-approval-amp-product-profile\">Regulatory Approval &amp; Product Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Ignis Therapeutics<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Cenobamate tablets<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Partial seizures in adult epilepsy patients<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Dual action: sodium channel blocker + GABAA receptor agonist<\/td><\/tr><tr><td><strong>Drug Generation<\/strong><\/td><td>Third-generation anti-seizure medication<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-presence-amp-china-licensing\">Global Presence &amp; China Licensing<\/h2>\n\n\n\n<p><strong>Geographic Reach:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Approved in <strong>24 countries<\/strong> including US, UK, Germany<\/li>\n\n\n\n<li>Trade names: <strong>Xcopri<\/strong> (US) \/ <strong>Ontozry<\/strong> (EU)<\/li>\n\n\n\n<li>Approved in <strong>Hong Kong SAR<\/strong> of China<\/li>\n<\/ul>\n\n\n\n<p><strong>Licensing Agreement:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Partner<\/strong>: SK Biopharmaceuticals<\/li>\n\n\n\n<li><strong>Deal Signed<\/strong>: November\u202f2021<\/li>\n\n\n\n<li><strong>Territory<\/strong>: Greater China (Mainland China, Hong Kong, Macau, Taiwan)<\/li>\n\n\n\n<li><strong>Rights<\/strong>: Exclusive development and commercialization<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-basis-phase-3-c035-study\">Clinical Basis: Phase 3 C035 Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Design<\/strong><\/td><td>Multi-center, randomized, double-blind, placebo-controlled Phase 3<\/td><\/tr><tr><td><strong>Study Name<\/strong><\/td><td>C035<\/td><\/tr><tr><td><strong>Global Centers<\/strong><\/td><td>70 centers across China, Japan, South Korea<\/td><\/tr><tr><td><strong>Total Patients<\/strong><\/td><td>519<\/td><\/tr><tr><td><strong>Chinese Patients<\/strong><\/td><td>227 (43.7% of total)<\/td><\/tr><tr><td><strong>Baseline<\/strong><\/td><td>Median 10 seizures per 28 days; 92% had \u22652 prior anti-seizure medications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-primary-efficacy-results-400mg-dose-group\">Primary Efficacy Results (400mg dose group)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><th>Comparison<\/th><\/tr><\/thead><tbody><tr><td><strong>Median seizure reduction<\/strong><\/td><td>100%<\/td><td>Significantly superior to placebo<\/td><\/tr><tr><td><strong>Seizure-free rate<\/strong><\/td><td>59.6%<\/td><td>Significantly superior to placebo<\/td><\/tr><tr><td><strong>Safety profile<\/strong><\/td><td>Good overall safety and tolerability<\/td><td>Mild-to-moderate adverse events<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-outlook\">Market Context &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Epilepsy Prevalence<\/strong>: <strong>9 million<\/strong> patients in China; partial seizures account for ~60% of cases<\/li>\n\n\n\n<li><strong>Market Gap<\/strong>: Limited third-generation options; cenobamate offers dual mechanism with proven efficacy<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: Differentiated from traditional sodium channel blockers through GABA-A agonism<\/li>\n\n\n\n<li><strong>Revenue Forecast<\/strong>: Analysts project <strong>\u00a5300-500 million<\/strong> (US$42-70 million) peak China sales by 2029<\/li>\n\n\n\n<li><strong>Launch Timeline<\/strong>: Commercial launch expected Q2\u202f2026 following pricing negotiations<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding cenobamate commercialization timelines and market potential. Actual results may differ due to regulatory, competitive, and reimbursement uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ignis Therapeutics announced that cenobamate tablets received marketing approval from China\u2019s National Medical Products Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50265,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4493,15],"class_list":["post-50264","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-ignis-therapeutics","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ignis Therapeutics announced that cenobamate tablets received marketing approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of partial seizures in adult patients with epilepsy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50264\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy\" \/>\n<meta property=\"og:description\" content=\"Ignis Therapeutics announced that cenobamate tablets received marketing approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of partial seizures in adult patients with epilepsy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50264\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-09T05:28:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-09T05:28:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0902.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50264#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50264\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy\",\"datePublished\":\"2025-12-09T05:28:20+00:00\",\"dateModified\":\"2025-12-09T05:28:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50264\"},\"wordCount\":287,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50264#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0902.webp\",\"keywords\":[\"Ignis Therapeutics\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50264#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50264\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50264\",\"name\":\"Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50264#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50264#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0902.webp\",\"datePublished\":\"2025-12-09T05:28:20+00:00\",\"dateModified\":\"2025-12-09T05:28:21+00:00\",\"description\":\"Ignis Therapeutics announced that cenobamate tablets received marketing approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of partial seizures in adult patients with epilepsy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50264#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50264\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50264#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0902.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0902.webp\",\"width\":1080,\"height\":608,\"caption\":\"Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50264#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy - Insight, China&#039;s Pharmaceutical Industry","description":"Ignis Therapeutics announced that cenobamate tablets received marketing approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of partial seizures in adult patients with epilepsy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50264","og_locale":"en_US","og_type":"article","og_title":"Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy","og_description":"Ignis Therapeutics announced that cenobamate tablets received marketing approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of partial seizures in adult patients with epilepsy.","og_url":"https:\/\/flcube.com\/?p=50264","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-09T05:28:20+00:00","article_modified_time":"2025-12-09T05:28:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0902.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50264#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50264"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy","datePublished":"2025-12-09T05:28:20+00:00","dateModified":"2025-12-09T05:28:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50264"},"wordCount":287,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50264#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0902.webp","keywords":["Ignis Therapeutics","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50264#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50264","url":"https:\/\/flcube.com\/?p=50264","name":"Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50264#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50264#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0902.webp","datePublished":"2025-12-09T05:28:20+00:00","dateModified":"2025-12-09T05:28:21+00:00","description":"Ignis Therapeutics announced that cenobamate tablets received marketing approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of partial seizures in adult patients with epilepsy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50264#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50264"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50264#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0902.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0902.webp","width":1080,"height":608,"caption":"Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50264#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0902.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50264"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50264\/revisions"}],"predecessor-version":[{"id":50266,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50264\/revisions\/50266"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50265"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}